Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.NTN · Entity 8278 | SVP Marketing | November 04, 2016 | November 08, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date November 04, 2016 · Filed November 08, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,131 |
Reported balance
After 2016-11-04 transaction · row 1
1 source rowRow 1 · 2016-11-04 · Grant · Acquired 7,531 · Balance 13,131 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2016 Filed Nov 8, 2016 00:40 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 7,531 | $6.64 | $50,005.84 |
DisclosureSEC source: 0001493152-16-014601 · form4.xml · nonDerivative · entry 1 Miller Dave Brian · CIK 0001673967 · SVP Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,131 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.